Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
about
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaFludarabine in the treatment of chronic lymphocytic leukemia: a reviewCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaObinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveTetraspanins as therapeutic targets in hematological malignancy: a concise reviewIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaA phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.Treatment with rituximab in benign and malignant hematologic disorders in children.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLFludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyThe clinical development of obinutuzumab for the treatment of follicular lymphoma.Rituximab: therapeutic benefit! Vitamin R?Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaModern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsRole of bendamustine in the treatment of chronic lymphocytic leukemia.Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Rituximab: mechanisms and applications.Rituximab: clinical development and future directions.The spectrum of use of rituximab in chronic lymphocytic leukemiaRole of rituximab in first-line treatment of chronic lymphocytic leukemia.Antibody therapy for chronic lymphocytic leukemia.An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Choosing first-line therapy for chronic lymphocytic leukemia.Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remissionExperience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.Clinical use of rituximab in haematological malignancies.
P2860
Q24617708-F39BAA07-C788-46A1-AD1D-3685AD309FD5Q24645173-75ACF618-32F8-4EE3-B756-4046B0359C02Q24681296-02546EEF-1C36-494A-AFF3-D082959EA9BBQ26781163-C0629399-F87E-4EC0-BB00-4EC671175D11Q26796455-76477684-6492-4B76-AD05-C6C8AC91199AQ27002353-D025E70E-7B92-4FB2-AE97-DD1B169CAFEBQ28306347-1CC44CF5-8998-43B9-B65B-7B4AC5D6D286Q30243968-241793B8-0887-4F92-9E1D-5CB2B3052FBEQ30417730-82AF4A70-502C-423C-B548-9B967A189753Q30421637-47C79367-DA91-4639-AAAA-4A62DBEE8E28Q30577607-57003CF3-AE7B-47B1-82A6-FBC34C042102Q33346607-65BEE190-3E30-4DD4-9BA2-58306DE02C1DQ33374660-D90AC36B-E214-4784-BBE7-C23C3C82CD3EQ33406478-F81F99A6-031F-4AF8-971D-8555A0E7B598Q33418091-789900DA-6315-4841-B14B-188282655FD4Q33424781-E1FA736C-953D-45D0-B070-A82FBFC57257Q33438428-6FCDFE4A-9680-4913-8F05-D9647A2066D6Q33565265-360FBEB8-CCFE-4183-B18D-552E67D9FF99Q33764056-DDB62FB9-4232-4B6B-AA89-E5D7B72B6CA9Q33846793-81C22E28-739B-4BBC-9984-3E602E49E31BQ33880538-9938E0DE-86D6-483C-AA44-54A2F9E6ADA1Q33905245-923E8E29-7B88-445C-892B-CBC86D466D16Q33913537-F446258A-616C-4E37-82FD-C92165616025Q33916026-B052BA32-61EB-43F9-9E8E-7C62B01CE8B3Q34009003-F68CA686-CA26-4EFC-8455-81B846BC1240Q34185125-F98B238C-BD5A-4000-8991-7F2DA082C7F2Q34310845-B5392322-8D65-494C-95BC-DF80C2B9D9A7Q34334943-D1A45185-1A27-4B22-9FE5-4ECE5A1B16A0Q34462378-3260EB4B-2D49-48D2-87D5-EB43959DD1D1Q34482081-562FC2B3-DADF-4424-ADA9-F26F80E1C06FQ34510030-1F4DB462-2644-4041-9D29-894B9366C3AEQ34574147-543ACB7C-A42C-4F35-8D62-D92E1D9F6795Q34589909-F053CFAE-F04D-45BE-9A39-FD80D130680EQ34773987-F2A6B3DD-7207-4536-AF17-BC71AD22D597Q34879367-6A031C0C-3ED5-4401-945B-5AB146889D38Q35124844-9A58C2DB-FA3A-41BE-9F60-56E4E324B7E0Q35211548-3287C96C-E28C-4B22-9639-86ECF55AA1A4Q35461949-B10FB9CB-8FE9-42CE-9954-9FF3D17FE30FQ35484992-0BF3344F-6753-42E4-ADB7-88AE29397BE7Q35561014-E860AB8D-3951-40E3-B937-5A20A7A1FB36
P2860
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Rituximab using a thrice weekl ...... ivity and acceptable toxicity.
@en
type
label
Rituximab using a thrice weekl ...... ivity and acceptable toxicity.
@en
prefLabel
Rituximab using a thrice weekl ...... ivity and acceptable toxicity.
@en
P2093
P921
P1476
Rituximab using a thrice weekl ...... ivity and acceptable toxicity.
@en
P2093
A Goodrich
A J Grillo-Lopez
J K Waselenko
J Rosenberg
P304
P356
10.1200/JCO.2001.19.8.2153
P407
P577
2001-04-01T00:00:00Z